Recommended

GSK appoints new CEO
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Regulatory-first for gene editing therapy

13
SHARES

The world’s first investigational in vivo CRISPR-based gene editing therapy cleared for late-stage clinical development is expected to enter Phase III in late 2023.

Regulatory-first for gene editing therapy

The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) in the US.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

“The US Food and Drug Administration (FDA)’s clearance “allows us to initiate a pivotal Phase III trial in the US, marking the first in vivo CRISPR-based candidate to begin late-stage clinical development,” Dr John Leonard, President and Chief Executive Officer of Intellia Therapeutics stated. He added that the company is “thrilled to further advance NTLA-2001… as we embark on a new era in medicine.”

As part of a collaboration with Regeneron Pharmaceuticals, Intellia Therapeutics leads the development and commercialisation of NTLA-2001.

Transthyretin (ATTR) amyloidosis is a rare congenital disease in which individuals have mutations in the TTR gene. This results in the liver producing structurally abnormal transthyretin (TTR) protein with a tendency to misfold. Build up of these damaged proteins as amyloid cause serious complications in tissues such as the heart, nerves and gastrointestinal system.

Gene editing therapy NTLA-2001

NTLA-2001, based on Nobel Prize-winning CRISPR/Cas9 technology, could be the first single-dose treatment for ATTR amyloidosis.

[NTLA-2001] is the first investigational CRISPR therapy candidate to be administered systemically, or through a vein, to edit genes inside the human body”

The gene editing therapy is the first investigational CRISPR therapy candidate to be administered systemically, or through a vein, to edit genes inside the human body.

According to Intellia Therapeutics, the treatment works by using lipid nanoparticles to deliver a two-part genome editing system to the liver: guide RNA specific to the disease-causing gene and messenger RNA that encodes the Cas9 enzyme, which carries out the precision editing.

Both preclinical and clinical data have demonstrated meaningful and long-lasting transthyretin (TTR) reduction following in vivo inactivation of the target gene. This supports NTLA-2001’s potential as a single-administration therapeutic. For example, a global Phase I trial is studying NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) or transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

The global Phase III study of the CRISPR-based gene editing therapy NTLA-2001 is expected to begin by the end of 2023.

EMA validates first regulatory submission for CRISPR-based medicine

Share via
Share via